Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
135.33
+2.31 (1.74%)
At close: Jul 10, 2025, 4:00 PM
134.01
-1.32 (-0.98%)
Pre-market: Jul 11, 2025, 7:25 AM EDT
Biogen Revenue
Biogen had revenue of $2.43B in the quarter ending March 31, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to $9.82B, up 1.59% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$9.82B
Revenue Growth
+1.59%
P/S Ratio
2.01
Revenue / Employee
n/a
Employees
n/a
Market Cap
19.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
BIIB News
- 1 day ago - Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - GlobeNewsWire
- 1 day ago - Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Business Wire
- 11 days ago - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy - GlobeNewsWire
- 13 days ago - New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA - GlobeNewsWire
- 16 days ago - Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results - GlobeNewsWire
- 18 days ago - Biogen: Investors Are Missing The Bigger Picture - Seeking Alpha
- 22 days ago - 20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks - Market Watch
- 23 days ago - Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - GlobeNewsWire